“Sana Alajmovic is the perfect match for Enzymatica. Her background in life sciences, strong drive, and proven commercial acumen makes her well suited to lead the company in the next phase. She combines strategic vision with a clear focus on results and has a rare ability to build partnerships and drive growth. We are very pleased to welcome her as our new CEO,” says Bengt Baron, Chairman of the Board, Enzymatica AB.

Sana Alajmovic

Sana Alajmovic is the co-founder and current CEO of Sigrid Therapeutics. She brings experience from business development and leadership within the life science sector, with a strong track record in commercializing research and developing strategic partnerships with international pharmaceutical and consumer health companies, states Enzymatica.

Related article

Sana Alajmovic – one of Sweden’s top female leaders

Sana Alajmovic, CEO and co-founder of Sigrid Therapeutics, has been appointed one of the Female Leaders of the Future. Sweden’s professional organization for executives – Ledarna – has presented its annual list of the country’s top female leaders. In its 14th consecutive year, the Framtidens kvinnliga ledare list compiles 75 top executives from a wide […]

“As the new CEO of Enzymatica, my focus is to lead the company into its next phase of growth. In a global market worth over SEK 300 billion, where competitors rely on outdated and generic products without clinically proven efficacy, I see great opportunities for Enzymatica to take a leading position with a unique, evidence-based alternative,” says Sana Alajmovic.

Sana Alajmovic will assume her new role no later than 31 January 2026.